John Chappel, MD
Professor of Psychiatry, University of Nevada Medical School
Fellow, American Society of Addiction Medicine
Dr. Chappel has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Dr. Chappel, you’ve been involved in addiction medicine for many years. What are some of the major advances that you’ve seen over that time?
When National Public Radio’s Science Friday devotes most of a program to a psychiatric study, it must be newsworthy. The STAR*D study got this special treatment recently, with Ira Flato interviewing John Rush about the ins and outs of the NIMH-funded project.
Because the first results from STAR*D make antidepressants look less powerful than we might have hoped, researchers have emphasized another aspect of the study – namely, that it represents a system that allows us to bring research techniques into our practices. A review of the STAR*D treatment manual is a useful exercise.
John Rush, MD
Professor of Psychiatry, University of Texas Southwestern Medical School
Principal Investigator and Study Director, STAR*D Trial
Dr. Rush has disclosed that he was or is a consultant for Bristol Myers Squibb, Cyberonics, GlaxoSmithKline, Neuronetics, Ono, Organon; was or is a member of the speakers bureau of Cyberonics, Forest and GlaxoSmithKline; and was or is a stock shareholder of Pfizer Pharmaceuticals. The editors of The Carlat Psychiatry Report have closely reviewed the content of Dr. Rush’s interview and have determined that there are no financial conflicts of interest regarding this educational activity.
Dr. Rush, thanks for agreeing to help us understand the STAR*D trial. You were the overall principal investigator of what I believe was the largest study in history comparing different antidepressants. Looking at the first set of results, are you encouraged by the findings?
There are several natural treatments out there that may be helpful in psychiatry. Recently, the British Journal of Psychiatry published a review of “complementary medicines in psychiatry,” (Br J Psychiatry 2006;188:109-121). Based on this paper and our own review of recent better quality studies, TCPR offers the following list of potentially useful natural treatments.
A number of natural treatments have been subjected to the same kinds of rigorous double blind studies required of conventional medications and they have fared poorly. Four of the most commercially popular of these treatments have received particularly harsh treatment from the scientific method.
David Mischoulon, MD, PhD
Assistant Professor of Psychiatry, Harvard Medical School
Director of Alternative Remedy Studies, Depression Clinical and Research Program, Massachusetts General Hospital
Dr. Mischoulon has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity. The author has disclosed that acupuncture has not been approved by the U.S. Food and Drug Administration for use in the treatment of depression or substance abuse. Please consult product labeling for the approved usage of this treatment.
Dr. Mischoulon, thank you for returning to the pages of The Carlat Psychiatry Report. I know that since our last interview, you have been involved in studying the use of acupuncture in psychiatry. Tell us about that.